Lonza Group AG Confirms 2024 Outlook Amid Strategic Expansions

Lonza Group AG reaffirmed its full-year 2024 outlook, maintaining flat year-on-year sales in constant exchange rates and a CORE EBITDA margin in the high 20s. The company reported strong commercial and operational performance in its CDMO business during Q3, despite soft demand in the Capsules & Health Ingredients and Bioscience sectors.

A notable development for Lonza was the acquisition of the Genentech manufacturing facility in Vacaville, US, from Roche for USD 1.2 billion. This addition is expected to strengthen Lonza’s mammalian manufacturing capabilities globally. The integration of the Vacaville site is proceeding as planned.

Additionally, Lonza's new large-scale mammalian facility in Visp, Switzerland, is fully contracted with agreements stretching to 2029, and operations are set to begin in H1 2025. The company also announced a significant contract with Vertex for supply of CASGEVY®, a groundbreaking gene-edited therapy.